Mayo Clinic
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.
Inclusion Criteria: * Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia * Patients willing to provide written informed consent Exclusion Criteria: * Unwillingness/unable to give blood samples
100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
Arctuva estimate
Verify or correct the compensation shown for this listing.